WO2003025175A3 - Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments - Google Patents

Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments Download PDF

Info

Publication number
WO2003025175A3
WO2003025175A3 PCT/IB2002/004208 IB0204208W WO03025175A3 WO 2003025175 A3 WO2003025175 A3 WO 2003025175A3 IB 0204208 W IB0204208 W IB 0204208W WO 03025175 A3 WO03025175 A3 WO 03025175A3
Authority
WO
WIPO (PCT)
Prior art keywords
tumour
apoptosis
reversion
virus resistance
medicines
Prior art date
Application number
PCT/IB2002/004208
Other languages
English (en)
Other versions
WO2003025175A2 (fr
Inventor
Adam Telerman
Robert Amson
Marius Tuijnder
Original Assignee
Molecular Engines Lab
Adam Telerman
Robert Amson
Marius Tuijnder
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Engines Lab, Adam Telerman, Robert Amson, Marius Tuijnder filed Critical Molecular Engines Lab
Publication of WO2003025175A2 publication Critical patent/WO2003025175A2/fr
Publication of WO2003025175A3 publication Critical patent/WO2003025175A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne notamment de nouvelles sequences impliquées dans les voies moléculaires de la suppression tumorale, la réversion tumorale, l'apoptose et/ou la résistance aux virus. Elle concerne également l'utilisation de ces sequences ou le traitement contre le cancer, maladies virales, maladies neurodégénératives ainsi qu'en matière de diagnostique ainsi que pour la mise en oeuvre de procèdes de criblage de composes a tester. Cette invention a également pour objet des procédés de détection et/ou de dosage des séquences de l'invention ou de leurs produits d'expression dans un prélèvement biologique.
PCT/IB2002/004208 2001-09-17 2002-09-17 Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments WO2003025175A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR01/111978 2001-09-17
FR0111978 2001-09-17

Publications (2)

Publication Number Publication Date
WO2003025175A2 WO2003025175A2 (fr) 2003-03-27
WO2003025175A3 true WO2003025175A3 (fr) 2003-06-12

Family

ID=8867342

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2002/004208 WO2003025175A2 (fr) 2001-09-17 2002-09-17 Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments

Country Status (1)

Country Link
WO (1) WO2003025175A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2453173A (en) 2007-09-28 2009-04-01 Dxs Ltd Polynucleotide primers
EP2151502A1 (fr) * 2008-07-30 2010-02-10 Lohmann Tierzucht GmbH Variations génétiques associées au comportement de becquetage chez les espèces aviaires
US10470446B2 (en) 2014-05-22 2019-11-12 Baylor College Of Medicine Engineered cell comprising a recombinant pro-methylation cis-element construct that resides in a regulatory region of a target gene

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997022695A2 (fr) * 1995-12-20 1997-06-26 Fondation Jean Dausset-Ceph Sequences nucleotidiques, proteines, medicaments et agents diagnostiques utiles dans le traitement du cancer
WO2000008147A1 (fr) * 1998-08-05 2000-02-17 Molecular Engines Laboratories Genes impliques dans les voies moleculaires de la suppression tumorale et/ou la resistance aux virus
WO2001055367A1 (fr) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Acides nucleiques, proteines et antigenes
WO2001059063A2 (fr) * 2000-01-31 2001-08-16 Human Genome Sciences, Inc. Acides nucleiques, proteines et anticorps
WO2002050286A2 (fr) * 2000-12-20 2002-06-27 Pe Corporation (Ny) Proteines proteases humaines isolees, molecules d'acide nucleique codant ces proteines, et utilisation de ces proteines

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997022695A2 (fr) * 1995-12-20 1997-06-26 Fondation Jean Dausset-Ceph Sequences nucleotidiques, proteines, medicaments et agents diagnostiques utiles dans le traitement du cancer
WO2000008147A1 (fr) * 1998-08-05 2000-02-17 Molecular Engines Laboratories Genes impliques dans les voies moleculaires de la suppression tumorale et/ou la resistance aux virus
WO2001055367A1 (fr) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Acides nucleiques, proteines et antigenes
WO2001057182A2 (fr) * 2000-01-31 2001-08-09 Human Genome Sciences, Inc. Acides nucleiques, proteines et anticorps
WO2001059063A2 (fr) * 2000-01-31 2001-08-16 Human Genome Sciences, Inc. Acides nucleiques, proteines et anticorps
WO2002050286A2 (fr) * 2000-12-20 2002-06-27 Pe Corporation (Ny) Proteines proteases humaines isolees, molecules d'acide nucleique codant ces proteines, et utilisation de ces proteines

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BRENNER SYDNEY ET AL: "Gene expression analysis by massively parallel signature sequencing (MPSS) on microbead arrays.", NATURE BIOTECHNOLOGY, vol. 18, no. 6, June 2000 (2000-06-01), pages 630 - 634, XP002199492, ISSN: 1087-0156 *
DATABASE EM_EST [online] EMBL; 6 February 1998 (1998-02-06), XP002236070, Database accession no. AA775155 *
DATABASE GENBANK [online] EMBL; 17 February 2001 (2001-02-17), XP002236069, Database accession no. AB038490 *
DATABASE GSN [online] 23 January 2002 (2002-01-23), XP002236068, Database accession no. ABA18595 *
DATABASE GSN [online] 7 November 2001 (2001-11-07), XP002236067, Database accession no. AAK73967 *
DATABASE GSN [online] 8 January 2002 (2002-01-08), XP002236066, Database accession no. AAL37522 *
KOBAYASHI K ET AL: "Structural organization, complete genomic sequences and mutational analyses of the Fukuyama-type congenital muscular dystrophy gene, fukutin", FEBS LETTERS, vol. 489, no. 2-3, 2 February 2001 (2001-02-02), pages 192 - 196, XP004248884, ISSN: 0014-5793 *

Also Published As

Publication number Publication date
WO2003025175A2 (fr) 2003-03-27

Similar Documents

Publication Publication Date Title
Swystun et al. Breast cancer chemotherapy induces the release of cell‐free DNA, a novel procoagulant stimulus
WO2004066941A3 (fr) Profils d'expression destines au cancer du colon et procedes d'utilisation
WO2007005874A3 (fr) Anticorps monoclonaux humains diriges contre un ligand de mort programmee de type 1(pd-l1)
WO2005100998A3 (fr) Marqueurs membranaires destines a etre utilises pour le diagnostic et le traitement du cancer
WO2004067570A3 (fr) Diagnostic et traitement du cancer de la prostate
WO2005059108A3 (fr) Profils d'expression geniques et procedes d'utilisation
WO2003004989A3 (fr) Compositions, trousses, et procedes d'identification, d'evaluation, de prevention, et de therapie pour le cancer du sein
WO2004106495A3 (fr) Compositions, kits et procedes d'identification, d'evaluation et de prevention, et therapie anticancereuse
WO2000043791A3 (fr) Detection rapide et efficace d'une agregation de proteines aberrantes dans des maladies neurodegeneratives
WO2007058968A3 (fr) Profils d’expression genique et procedes d’utilisation
WO2009019370A3 (fr) Procede de dosage de l'apolipoproteine aii pour le diagnostic in vitro du cancer colorectal
WO2005032495A8 (fr) Profils d'expression genique et leurs methodes d'utilisation
WO2004078035A3 (fr) Profiles d'expression pour le cancer du sein et methodes d'utilisation
WO2003016464A3 (fr) Sequences d'oligosaccharides specifiques pour le cancer et leur utilisation
WO2004046332A3 (fr) Genes amplifies impliques dans un cancer
WO2003028631A3 (fr) Cibles medicamenteuses destinees a la maladie d'alzheimer et a d'autres maladies associees a une diminution du metabolisme neuronal
WO2005005661A3 (fr) Genes regules dans le cancer de l'ovaire utilises comme cibles pronostique et therapeutique
WO2008008983A3 (fr) Procédés et acides nucléiques pour des analyses de problèmes de la prolifération cellulaire
WO2003040369A3 (fr) Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments
WO2002064731A3 (fr) Sequences impliquees dans les phenomenes de suppression tumorale reversion tumorale apoptose et/ou resistance aux virus et leur utilisation comme medicaments
WO2007071829A3 (fr) Méthodes et moyens relatifs à des maladies
WO2003025175A3 (fr) Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments
ATE333521T1 (de) Detektion von vancomycin-resistenten enterococcus-subspezies
WO2003025176A8 (fr) Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments
WO2006099365A3 (fr) Polymorphismes genetiques associes a des maladies cardiaques coronariennes, methodes de detection et d'utilisation desdits polymorphismes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FR GB GR IE IT LU MC NL PT SE SK TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP